Social Capital Suvretta Holdings Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the biotechnology industry. The company was incorporated in 2021 and is based in Henderson, Nevada.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
3/A - Akili, Inc. (0001850266) (Issuer)
3/A - Akili, Inc. (0001850266) (Issuer)
3/A - Akili, Inc. (0001850266) (Issuer)
3/A - Akili, Inc. (0001850266) (Issuer)
3/A - Akili, Inc. (0001850266) (Issuer)
3/A - Akili, Inc. (0001850266) (Issuer)
3/A - Akili, Inc. (0001850266) (Issuer)
3/A - Akili, Inc. (0001850266) (Issuer)
4 - Akili, Inc. (0001850266) (Issuer)
4 - Akili, Inc. (0001850266) (Issuer)
424B3 - Akili, Inc. (0001850266) (Filer)
8-K - Akili, Inc. (0001850266) (Filer)
424B3 - Akili, Inc. (0001850266) (Filer)
8-K - Akili, Inc. (0001850266) (Filer)
8-K/A - Akili, Inc. (0001850266) (Filer)
8-K - Akili, Inc. (0001850266) (Filer)
424B3 - Akili, Inc. (0001850266) (Filer)
10-Q - Akili, Inc. (0001850266) (Filer)
424B3 - Akili, Inc. (0001850266) (Filer)
8-K - Akili, Inc. (0001850266) (Filer)
Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac
Akili, Inc. common stock to begin trading on Nasdaq under the ticker symbol "AKLI" on August 22, 2022 Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatment and advancement of late-stage pipeline Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I ("SCS") (NASDAQ:DNAA), a publicly traded special purpose acquisition company. The newly formed company, Akili, Inc. ("Akili"), is expected to start trading on The Nasdaq Capital Market ("Nasdaq") under the new ticker symbol "AKLI" on August 22, 2022. Akili raised more than $163 million from the
New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced the nominees for its future board of directors, effective upon the closing of Akili's business combination with Social Capital Suvretta H
New and recent director nominees include industry trailblazers BJ Jones, Christine Lemke, Ken Ehlert and Chamath Palihapitiya Akili Interactive ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced the nominees for its future board of directors, effective upon the closing of Akili's business combination with Social Capital Suvretta Holdings Corp. I ("SCS") (NASDAQ:DNAA), subject to customary closing conditions. Shares of the new public company's common stock are expected to trade on Nasdaq under the symbol "AKLI." Akili's public company board of directors is expected to consist of seven director
The Roblox vision for bringing people together through shared experiences, plus the Akili commitment to a new era of cognitive medicine, make the companies ideal partners to deliver a reimagined patient experience Akili Interactive ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, and Roblox (NYSE:RBLX), a global platform bringing millions of people together through shared experiences, today announced a collaboration that connects patients' medical treatments to their favorite virtual worlds. "Roblox brings together tens of millions of people every day to connect, create, and express themselves, and we're p
Strong capital base with PureTech level cash and cash equivalents of $418.9 million1 and consolidated cash and cash equivalents of $465.7 million2 as of December 31, 2021 Rapidly progressing pipeline of 27 therapeutics and therapeutic candidates, across Wholly Owned and Founded Entity programs, with 11 clinical trials initiated and 6 clinical trial readouts in 2021 Founded Entities continuing to mature and generate value for PureTech, with three now publicly traded and a fourth soon expected to go public Reviewing capital allocation strategy to drive additional value to shareholders with potential returns of capital through various mechanisms Company to host a webcast and conference cal
AKL-T03 showed a statistically significant improvement in sustained attention compared to control intervention AKL-T03 is built on the same technology engine as Akili's digital therapeutic EndeavorRx, which has been cleared by the U.S. Food and Drug Administration (FDA) for use in children with ADHD (see full indication below) PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading cognitive medicine company improving health through game-changing technologies, today announced that the American Journal of Psychiatry has published findings from the
AKL-T03 showed a statistically significant improvement in sustained attention compared to control intervention AKL-T03 is built on the same technology engine as Akili's digital therapeutic EndeavorRx, which has been cleared by the U.S. Food and Drug Administration (FDA) for use in children with ADHD (see full indication below) Akili Interactive ("Akili"), a leading cognitive medicine company improving health through game-changing technologies, today announced that the American Journal of Psychiatry has published findings from the STARS-MDD clinical trial evaluating Akili's AKL-T03 digital therapeutic as a potential treatment for attention impairments in adults with major depressive disord
Akili Interactive ("Akili" or the "Company"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced that management will present at Chardan's Prescription Digital Therapeutics Half-Day Summit on Monday, April 11, 2022 at 2:00 p.m. E.T. More information on the event can be found here. About Akili Akili is pioneering the development of cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced lik
Jon David brings deep expertise in building and launching engaging products to the Akili leadership team PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where
Jon David brings deep expertise in building and launching engaging products to the Akili leadership team PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where
Jon David brings deep expertise in building and launching engaging products to the Akili leadership team Akili Interactive ("Akili" or the "Company"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where the treatment is experienced like high-end entertainment. Reporting to the CEO, David will join the Akili executive team, which includes leader
In addition to PureTech's advanced Wholly Owned Pipeline, Founded Entities are an additional source of value and Akili is now set to join the growing list of publicly-traded Founded Entities for PureTech, which also include Karuna Therapeutics (NASDAQ:KRTX), Vor Biopharma (NASDAQ:VOR) and Gelesis (NYSE:GLS) Fully committed PIPE of $162 million led by $100 million from Social Capital with remaining $62 million from new and existing investors including: Suvretta Capital Management's Averill strategy, Apeiron Investment Group, Temasek, co-founder PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners and Omidyar Technology Ventures Transaction values the combined co
Akili's leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and delivered Transaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases, including expanded ADHD populations, multiple sclerosis, autism, and depression Transaction values the combined company at an equity value post-money of up to approximately $1 billion and is expected to provide up to $412 million in
SC 13G - Akili, Inc. (0001850266) (Subject)
SC 13D - Akili, Inc. (0001850266) (Subject)
SC 13G - Akili, Inc. (0001850266) (Subject)
SC 13G - Akili, Inc. (0001850266) (Subject)
SC 13D - Akili, Inc. (0001850266) (Subject)
SC 13G/A - Akili, Inc. (0001850266) (Subject)
SC 13G - Social Capital Suvretta Holdings Corp. I (0001850266) (Subject)
SC 13G - Social Capital Suvretta Holdings Corp. I (0001850266) (Subject)
SC 13G - Social Capital Suvretta Holdings Corp. I (0001850266) (Subject)
SC 13G/A - Social Capital Suvretta Holdings Corp. I (0001850266) (Subject)